American Diabetes Association
Online-only_Supplemental_Material.pdf (152.61 kB)

Accuracy of a Factory-Calibrated Continuous Glucose Monitor in Individuals With Diabetes on Hemodialysis

Download (152.61 kB)
posted on 2022-04-29, 13:14 authored by Orianne Villard, Marc D. Breton, Swati Rao, Mary K. Voelmle, Morgan R. Fuller, Helen E. Myers, Ryan K. McFadden, Zander S. Luke, Christian A. Wakeman, Mary Clancy-Oliveri, Ananda Basu, Meaghan M. Stumpf
Objective: Continuous glucose monitoring (CGM) improves diabetes management, but its reliability in individuals on hemodialysis is poorly understood and potentially affected by interstitial and intravascular volume variations.

Methods: We assessed the accuracy of a factory-calibrated CGM, using venous blood glucose measurements (vBGM) during hemodialysis sessions and self-monitoring blood glucose (SMBG) at home.

Results: Twenty participants completed the protocol. The mean absolute relative difference of the CGM was 13.8% and 14.4% when calculated on SMBG (n=684) and on vBGM (n=624), and 98.7% and 100% of values in the Parkes error grid A/B zones, respectively. Throughout 181 days of CGM monitoring, the median time in range (70-180mg/dL) was 38.5% (IQR: 29.3-57.9), with 28.7% (7.8-40.6) of the time >250mg/dL.

Conclusions. The overall performance of a factory-calibrated CGM appears reasonably accurate and clinically relevant for use in practice by individuals on hemodialysis and health professionals to improve diabetes management.


Dexcom provided devices and financial support for this study but had no role in the data collection, analysis, and findings. This work was also supported by University of Virginia and O.V. is supported in part by a grant from the Société Francophone du Diabète.


Usage metrics

    Diabetes Care


    Ref. manager